Epigenetic modification is linked to Alzheimer's disease: Is it a maker or a marker?

BMB Reports

Volumn 43, Issue 10, 2010, Pages 649-655

  Lee, Junghee ^a,b   Ryu, Hoon ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Alzheimer's disease; Chromatin remodeling; DNA methylation; Epigenetic modification

Indexed keywords

BIOLOGICAL MARKER; SIRTUIN;

ALZHEIMER DISEASE; ANIMAL; BIOLOGICAL MODEL; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; SIRTUINS;

EID: 78649453960     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.3858/BMBRep.2010.43.10.649     Document Type: Review

References (51)

1. Marques, S. C., Oliveira, C. R., Outeiro, T. F. and Pereira, C. M. (2010) Alzheimer's disease: the quest to understand complexity. J. Alzheimers. Dis. 21, 373-383.
2. Chouliaras, L., Rutten, B. P., Kenis, G., Peerbooms, O., Visser, P. J., Verhey, F., van Os, J., Steinbusch, H. W. and van den Hove, D. L. (2010) Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog. Neurobiol. 90, 498-510.
3. Suzuki, M. M. and Bird, A. (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9, 465-476.
4. Tohgi, H., Utsugisawa, K., Nagane, Y., Yoshimura, M., Genda, Y. and Ukitsu, M. (1999) Reduction with age in methylcytosine in the promoter region -224 approximately -101 of the amyloid precursor protein gene in autopsy human cortex. Brain Res. Mol. Brain Res. 70, 288-292.
5. West, R. L., Lee, J. M. and Maroun, L. E. (1995) Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J. Mol. Neurosci. 6, 141-146.
6. Wang, S. C., Oelze, B. and Schumacher, A. (2008) Age-specific epigenetic drift in late onset Alzheimer's disease. PLoS ONE 3, e2698.
7. Poulsen, P., Esteller, M., Vaag, A. and Fraga, M. F. (2007) The epigenetic basis of twin discordance in age-related diseases. Pediatr. Res. 61, 38R-42R.
8. Mastroeni, D., McKee, A., Rogers, J. and Coleman, P. D. (2009) Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 4, e6617.
9. Silva, P. N., Gigek, C. O., Leal, M. F., Bertolucci, P. H., de Labio, R. W., Payão, S. L. and Smith Mde, A. (2008) Promoter methylation analysis of SIRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer's disease. J. Alzheimers. Dis. 13, 173-176.
10. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I. R., McGeer, P. L., O'Banion, M. K., Pachter J, Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G. and Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
11. Bannister, A. J., Schneider, R. and Kouzarides, T. (2002) Histone methylation: dynamic or static? Cell 109, 801-806.
12. Felsenfeld, G., and Groudine, M. (2003) Controlling the double helix. Nature 421, 448-453.
13. Hake, S. B., Xiao, A. and Allis, C. D. (2004) Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer 90, 761-769.
14. Jenuwein, T. and Allis, C. D. (2001) Translating the histone code. Science 293, 1074-1080.
15. Sadri-Vakili, G. and Cha, J. H. (2006) Mechanisms of disease: histone modifications in Huntington's disease. Nat. Clin. Pract. Neurol. 2, 330-338.
16. Mattson, M. P. and Sherman, M. (2003) Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation. Neuromolecular. Med. 4, 109-132.
17. Robakis, N. K. (2003) An Alzheimer's disease hypothesis based on transcriptional dysregulation. Amyloid. 10, 80-85.
18. Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D. and Rumbaugh, G. (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870-880.
19. Ogawa, O., Zhu, X., Lee, H. G., Raina, A., Obrenovich, M. E., Bowser, R., Ghanbari, H. A., Castellani, R. J., Perry, G. and Smith, M. A. (2003) Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta. Neuropathol. 105, 524-528.
20. +/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42, 947-959.
21. Korzus, E., Rosenfeld, M. G. and Mayford, M. (2004) CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42, 961-972.
22. Oliveira, A. M., Wood, M. A., McDonough, C. B. and Abel, T. (2007) Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits. Learn. Mem. 14, 564-572.
23. Strahl, B. D. and Allis, C. D. (2000) The language of covalent histone modifications. Nature 403, 41-45.
24. Hake, S. B. and Allis, C. D. (2006) Histone H3 variants and their potential role in indexing mammalian genomes: the 'H3 barcode hypothesis'. Proc. Natl. Acad. Sci. U.S.A. 103, 6428-6435.
25. Papp, B. and Muller, J. (2006) Histone trimethylation and the maintainence of transcriptional ON and OFF states by trxG and PcG proteins. Genes Dev. 20, 2041-2054.
26. Ferrante, R. J., Kubilus, J. K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi-Carter, R. and Hersch, S. M. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427.
27. Gardian, G., Browne, S. E., Choi, D. K., Klivenyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B., Ratan, R. R., Ferrante, R. J. and Beal, M. F. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280, 556-563.
28. McCampbell, A., Taye, A. A., Whitty, L., Penney, E., Steffan, J. S. and Fischbeck, K. H. (2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Natl Acad. Sci. U.S.A. 98, 15179-15184.
29. Ryu, H., Smith, K., Camelo, S. I., Carreras, I., Lee, J., Iglesias, A. H., Dangond, F., Cormier, K. A., Cudkowicz, M. E., Brown, R. H. Jr. and Ferrante, R. J. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93, 1087-1098.
30. Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y. Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L. and Thompson, L. M. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743.
31. Hockly, E., Richon, M. V., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K, Ghazi-Noori, S., Mahal, A., Lowden, P. A., Steffan, J. S., Marsh, J. L., Thompson, L. M., Lewis, C. M., Marks, P. A. and Bates, G. P. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 2041-2046.
32. Hahnen, E., Hauke, J., Tränkle, C., Eyüpoglu, I. Y., Wirth, B. and Blümcke, I. (2008) Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert. Opin. Investig. Drugs. 17, 169-184.
33. Guan, J. S., Haggarty, S. J., Giacometti, E., Dannenberg, J. H., Joseph, N., Gao, J., Nieland, T. J., Zhou, Y., Wang, X., Mazitschek, R., Bradner, J. E., DePinho, R. A., Jaenisch, R. and Tsai, L. H. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 7, 55-60.
34. Julien, C., Tremblay, C., Emond, V., Lebbadi, M., Salem, N. Jr., Bennett, D. A. and Calon, F. (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol. 68, 48-58.
35. Donmez, G., Wang, D., Cohen, D. E. and Guarente, L. (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142, 320-332.
36. Wolfe, M. S. and Selkoe, D. J. (2010) Giving Alzheimer's the old one-two. Cell 142, 194-196.
37. Albani, D., Polito, L. and Forlon, I. G. (2010) Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J. Alzheimers. Dis. 19, 11-26.
38. De Oliveira, R. M., Pais, T. F. and Outeiro, T. F. (2010) Sirtuins: common targets in aging and in neurodegeneration. Curr. Drug. Targets. 11, 1270-1280.
39. Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M. and LaFerla, F. M. (2008) Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 28, 11500-11510.
40. Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L. and Gu, W. (2001) Negative control of p53 by Sir2 alphapromotes cell survival under stress. Cell 107, 137-148.
41. Karuppagounder, S. S., Pinto, J. T., Xu, H., Chen, H. L., Beal, M. F. and Gibson, G. E. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 54, 111-118.
42. Markus, M. A. and Morris, B. J. (2008) Resveratrol in prevention and treatment of common clinical conditions of aging. Clin. Interv. Aging. 3, 331-339.
43. Ryan, K. A. and Pimplikar, S. W. (2005). Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J. Cell Biol. 171, 327-335.
44. Munoz, D. G., Wang, D. and Greenberg, B. D. (1993) Hirano bodies accumulate C-terminal sequences of beta-amyloid precursor protein (beta-APP) epitopes. J. Neuropathol. Exp. Neurol. 52, 14-21.
45. Artavanis-Tsakonas, S., Rand, M. D. and Lake, R. J. (1999) Notch signaling: cell fate control and signal integration in development. Science 284, 770-776.
46. McLoughlin, D. M. and Miller, C. C. (1996) The intracellular cytoplasmic domain of the Alzheimer's disease amyloid precursor protein interacts with phosphotyrosine-binding domain proteins in the yeast two-hybrid system. FEBS Lett. 397, 197-200.
47. Cao, X. and Sudhof, T. C. (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293, 115-120.
48. Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H., Glass, C. K. and Rosenfeld, M. G. (2002) Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappa B and beta-amyloid precursor protein. Cell 110, 55-67.
49. Siegmund, K. D., Connor, C. M., Campan, M., Long, T. I., Weisenberger, D. J., Biniszkiewicz, D., Jaenisch, R., Laird, P. W. and Akbarian, S. (2007) DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One 2, e895.
50. Abdolmaleky, H. M., Smith, C. L., Faraone, S. V., Shafa, R., Stone, W., Glatt, S. J. and Tsuang, M. T. (2004) Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 127B, 51-59.
51. Ryu, H., Lee, J., Hagerty, S. W., Soh, B. Y., McAlpin, S. E., Cormier, K. A., Smith, K, M. and Ferrante, R. J. (2006) ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 103, 19176-19181.